IKZF1 deletion + CDKN2A deletion
|
AML
|
IKZF1 deletion + CDKN2A deletion
|
AML
|
ponatinib Resistant: C3 – Early Trials
|
ponatinib Resistant: C3 – Early Trials
|
IKZF1 deletion + CDKN2A deletion
|
ALL
|
IKZF1 deletion + CDKN2A deletion
|
ALL
|
dasatinib + blinatumomab Sensitive: C3 – Early Trials
|
dasatinib + blinatumomab Sensitive: C3 – Early Trials
|